Main Uses and Benefits of Merional 75 IU

Merional 75 IU is a medication containing highly purified human menopausal gonadotropin (hMG). It is primarily used in the field of reproductive medicine to address hormonal imbalances and support the physiological processes required for conception.

Treatment of Female Infertility

In women, Merional 75 IU is used to stimulate the ovaries to produce and develop mature follicles. Its main applications include:

• Anovulation: It is used for women who do not ovulate or who have not responded to other treatments, such as clomifene citrate. The medication provides the necessary hormones—Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH)—to trigger follicle growth.
• Assisted Reproductive Technologies (ART): The medication is a key component in controlled ovarian hyperstimulation protocols for procedures such as In Vitro Fertilization (IVF), Gamete Intra-Fallopian Transfer (GIFT), and Intracytoplasmic Sperm Injection (ICSI). In these cases, it helps the ovaries produce multiple eggs simultaneously.

Treatment of Male Infertility

Merional 75 IU is also used in the treatment of specific types of male infertility. Its primary role is to address deficiencies in hormone production that affect reproductive health:

• Hypogonadotropic Hypogonadism: The medication may be used to stimulate sperm production (spermatogenesis) in men whose bodies do not produce sufficient levels of gonadotropins. It is often used in conjunction with other hormonal therapies to support the maturation of sperm cells.

Primary Benefits

The primary benefit of Merional 75 IU is its ability to mimic the natural actions of the pituitary gland's hormones. By providing a balanced ratio of FSH and LH, it supports the essential stages of the reproductive cycle that are otherwise hindered by hormonal insufficiencies. This helps create the biological conditions necessary for either natural conception or successful assisted reproduction.

Merional 75 IU is officially labeled for use in adult women of reproductive age who require ovarian stimulation for anovulation or during Assisted Reproductive Technology (ART) procedures. Use in men with hypogonadotrophic hypogonadism is also documented in some regions. The regulatory label defines specific contraindications and eligibility limitations.

Contraindications and Prohibited Use

Category	Regulatory Status (Must Not Use)
Absolute Contraindications	Patients with known hypersensitivity to menotropins, or those with tumours of the pituitary gland or hypothalamus.
Pregnancy and Lactation	Use is contraindicated (prohibited) in women who are currently pregnant or breastfeeding.
Comorbidity Restrictions	Women with certain sex hormone-dependent tumours (ovarian, uterine, or mammary carcinoma) or unexplained gynaecological bleeding.

Age and Condition Limitations

Use in pediatric and geriatric populations is officially categorized as having no relevant use. Additionally, safety and efficacy have not been established in patients with renal impairment or hepatic impairment, as explicitly noted in regulatory prescribing information. Treatment is also not recommended for women with primary ovarian failure or anatomical conditions, such as malformation of sexual organs, that are incompatible with achieving a successful pregnancy.

Interactions with other medicines and products

Official regulatory information for Merional 75 IU (Menotropins) focuses on pharmacodynamic constraints and the explicit absence of certain pharmacokinetic data.

---

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions:	Gonadotropins and Human Chorionic Gonadotropin (hCG).
Specific interacting medicines (if explicitly listed):	Urofollitropin and Human Chorionic Gonadotropin (hCG).
Mechanistic basis of interactions:	Pharmacodynamic Additive Effect (combining hormonal signals). No human drug-drug interaction studies have been conducted for Menotropins; therefore, no documented information exists for CYP-enzyme or transporter-mediated interactions.
Timing-based interaction rules:	The subsequent administration of hCG must be withheld if monitoring suggests a heightened risk of Ovarian Hyperstimulation Syndrome (OHSS), a critical outcome linked to the preceding Menotropins therapy.
Population-specific interaction notes:	Interaction relevance in individuals with renal insufficiency or hepatic insufficiency has not been established in formal studies.

---

Official Interaction Statements

• The co-administration of Menotropins with other gonadotropins, such as Urofollitropin, is an officially documented therapeutic pattern based on a required pharmacodynamic additive effect.
• The regulatory label contains no formally listed contraindicated drug-drug combinations in the interaction section.

The overall interaction profile is characterized by the lack of documented pharmacokinetic data and the focus on mandatory procedural and outcome-based constraints involving other fertility agents.

The following content adheres strictly to the mechanistic requirements.

How Merional 75 IU Works

Merional 75 IU exerts its effects through direct agonism on specific G protein-coupled receptors within the ovaries, initiating a cascade that modulates follicular growth and steroidogenesis.

---

Dual Agonism and Cellular Proliferation

The molecule provides activity that acts as a direct agonist for the Follicle-Stimulating Hormone Receptor ( FSHR) on granulosa cells and the Luteinizing Hormone/Choriogonadotropin Receptor ( LHCGR) on theca cells. FSHR activation triggers the cAMP-PKA signaling cascade, which rapidly accelerates granulosa cell mitosis (proliferation) and differentiation, contributing to the physical growth of the ovarian structures.

---

Two-Cell Synergy and Steroidogenesis Enhancement

The mechanism is defined by the synergy between the two activities. LH activity stimulates theca cells to produce androgen precursors, while FSH activity upregulates the aromatase enzyme in granulosa cells, which converts those precursors into estrogens (e.g., estradiol). This essential cooperation leads to a rapid, coordinated, and pronounced increase in estrogen synthesis, which reflects the maturation of multiple functional follicles.

---

Receptor Dependency and Mechanistic Constraint

The entire biological action is receptor-dependent, meaning it requires the presence of viable ovarian tissue that expresses functional FSHR and LHCGR. This mechanism is constrained in situations like primary ovarian dysfunction, where the fundamental biological targets necessary for the agonistic signal to transduce and create the resulting physiological effect are absent or significantly impaired.

How to use Merional 75 IU — Administration Guidelines

This medication is a potent gonadotrophin intended for use only under the close supervision of a physician experienced in fertility disorders. The dosing is highly individualized based on patient response, as determined by routine clinical monitoring (ultrasound and/or oestradiol levels).

---

Administration Scope

Administration Detail	Guideline
Route of Administration	Intramuscular (IM) or Subcutaneous (SC) injection
Preparation Requirements	The lyophilized powder must be reconstituted with the provided solvent immediately prior to use. The solution must be clear and colorless, without particles.
Age-Group Use	For use in adults only (no relevant use in the pediatric or elderly population).

Dosing Rules (for Women with Anovulation)

Procedural Step	Guideline
Initial Dose	Typically 75–150 IU daily, starting within the first 7 days of the menstrual cycle.
Dose Adjustment	Dose is adjusted according to ovarian response; adjustments should not be made more frequently than every 7 days, with a maximum daily dose typically not higher than 225 IU.
Final Step (Ovulation Induction)	When an optimal response is obtained, a single injection of 5,000–10,000 IU of hCG is administered 24–48 hours after the final Merional injection.

Connection to the Overall Use Protocol

Merional is administered as part of a closely monitored cycle, requiring the patient to adhere to a strict daily injection schedule and attend regular appointments for clinical monitoring. The administration is a two-phase process: first, daily Merional injections to stimulate follicular growth, and second, a single Human Chorionic Gonadotrophin (hCG) injection to trigger final follicular maturation and ovulation. The treatment cycle is abandoned if an adequate response is not achieved after a defined period or if the response is excessive.

Merional 75 IU: Recent Clinical Evidence

---

Overview of Clinical Research

This section outlines the key clinical research that has evaluated Menotropin (hMG), the active ingredient in Merional 75 IU, and its characteristics reported in the research. Menotropin is a highly purified preparation containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity.

Key Study Findings

Randomized Controlled Trials (RCTs) have examined whether Menotropin was associated with changes in symptoms during controlled ovarian stimulation (COS) for assisted reproductive technology (ART). Key findings from these studies include:

• Oocyte Yield: One multicenter, prospective RCT evaluated the highly purified Menotropin preparation (Merional-HG) against another hMG product. The findings suggested both preparations were comparable in the number of oocytes retrieved (the primary endpoint).
• Oocyte Quality: The same study recorded a higher percentage of mature oocytes reported in the participants treated with Merional-HG compared to the comparator group.
• Dosing: Analysis indicated that a reduced quantity of the gonadotropins administered per cycle was needed for the Merional-HG group to achieve similar outcomes compared to the reference treatment.

Comparative Studies

Further research has been conducted comparing highly purified Menotropin (hMG) preparations to recombinant FSH (rFSH) in patients undergoing ART. Findings from these comparative non-inferiority trials suggested:

Outcome Measured	Finding in hMG (Merional-HG) vs. rFSH	Context
Ongoing Pregnancy Rate	Comparable across treatment groups.	Assessed at 10–11 weeks gestation.
Adverse Events	Some studies recorded a lower overall incidence of Ovarian Hyperstimulation Syndrome (OHSS) in patients treated with hMG.	Observed in specific high-responder patient populations.

These studies primarily focus on women undergoing in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles. The research population did not typically include participants with primary ovarian failure.

Common questions about Merional 75 IU (FAQ)

---

Q: How long does it typically take from the start of Merional treatment until the final hCG injection to trigger ovulation?

According to official product information, treatment to stimulate the ovaries typically begins within the first seven days of the menstrual cycle and continues for at least seven days. The actual time needed to reach the stage for the final hCG injection varies, but it commonly ranges between 5 and 20 days, depending on the patient's individual ovarian response.

---

Q: What is the full list of ingredients in Merional 75 IU (including excipients)?

Official regulatory documents state that the medicine's powder contains the active ingredient, Menotropins, along with inactive ingredients (excipients) such as lactose and polysorbate 20. The provided solvent is a solution of sodium chloride (salt) and water for injection, and other ingredients used to balance the solution.

---

Q: How quickly should I administer the Merional injection after I have mixed the powder with the solvent?

Official product information emphasizes that the powder must be mixed with the solvent (reconstituted) immediately before use. The reconstituted solution should be administered right away. Any unused portion of the solution that remains after the injection should be properly discarded.

---

Q: What specific type of ultrasound is used for the clinical monitoring of the ovarian response?

The official product information requires regular monitoring using ultrasound to check for ovarian response. This clinical monitoring is typically performed using transvaginal ultrasonography (TVS) to accurately measure the number and size of the developing follicles in the ovaries.

---

Q: Can I take Merional if I am currently breastfeeding or pregnant?

No. Use of this medicine is contraindicated (prohibited) for women who are currently pregnant or breastfeeding. This information is clearly stated in the official regulatory documents for the medicine.

---

Q: What should I do with the used needles and syringes after the injection?

Regulatory instructions require that all used needles and syringes must be safely placed into a designated puncture-proof sharps container. The full sharps container, as well as any expired or unused medicine, should then be disposed of according to local laws and requirements for pharmaceutical waste.

---

Q: What is the maximum dose of Merional that a woman can receive in a single day for anovulation treatment?

According to official regulatory information for treating anovulation (Ovulation Induction), the maximum daily dose should typically not be higher than 225 IU. For other procedures, such as Assisted Reproductive Technology (ART), official documents indicate that higher doses may be used.

How to Store and Dispose of Merional 75 IU

Official regulations require strict adherence to storage and disposal guidelines for Merional 75 IU (Menotropins).

---

Storage Requirements

• Temperature and Environment: The powder must be stored in its original packaging at a temperature not exceeding 25 C and must not be frozen. The product requires protection from light.
• Child Safety: Merional 75 IU must be kept out of the sight and reach of children.
• Stability: The solution must be administered immediately after reconstitution (mixing). Any unused portion remaining after injection must be discarded.

---

Disposal Instructions

• Pharmaceutical Waste: Used needles and syringes must be placed into a designated puncture-proof sharps container.
• Final Disposal: Unused medicine, expired product, and the sealed sharps container must be disposed of according to local requirements and state or local laws for pharmaceutical waste.